Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: Localized scleroderma, systemic sclerosis and overlap syndromes
: Knobler Robert, Geroldinger-Simic Marija, Kreuter Alexander, Hunzelmann Nicolas, Moinzadeh Pia, Rongioletti Franco, Denton Christopher, Mouthon Luc, Cutolo Maurizio, Smith Vanessa, Gabrielli Armando, Bagot Martine, Olesen Anne B., Foeldvari Ivan, Jalili Ahmad, Kähäri Veli Matti, Karpati Sarolta, Kofoed Kristian, Olszewska Malgorzata, Panelius Jaana, Quaglino Pietro, Seneschal Julien, Sticherling Michael, Sunderkotter Cord, Tanew Adrian, Wolf Peter, Worm Margitta, Skrok Anna, Rudnicka Lidia, Krieg Thomas
Publisher: Wiley-Blackwell
: 2024
: Journal of the European Academy of Dermatology and Venereology
: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
: 38
: 7
: 1251
: 1280
: 0926-9959
: 1468-3083
DOI: https://doi.org/10.1111/jdv.19912
: https://doi.org/10.1111/jdv.19912
The term 'sclerosing diseases of the skin' comprises specific dermatological entities, which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement and can sometimes be difficult to distinguish from each other. The present consensus provides an update to the 2017 European Dermatology Forum Guidelines, focusing on characteristic clinical and histopathological features, diagnostic scores and the serum autoantibodies most useful for differential diagnosis. In addition, updated strategies for the first- and advanced-line therapy of sclerosing skin diseases are addressed in detail. Part 1 of this consensus provides clinicians with an overview of the diagnosis and treatment of localized scleroderma (morphea), and systemic sclerosis including overlap syndromes.
